Skip to main content

Table 1 Characteristics of studies included in the meta-analysis

From: Prognostic significance of 8-hydroxy-2′-deoxyguanosine in solid tumors: a meta-analysis

Author

Region

Cancer Type

Sample size

Tumor stage

Follow-up (month)

Outcome measure

Expression associates with poor prognosis

Assay

Cut-off value

Location of 8-oxo-dG

Survival analysis

NOS score

Method*

Li et al. 2012 [22]

China

Hepatocellular carcinoma

103

I-IV

36

OS

High

IHC

percentage of positive tumor cells

Nuclei

multivariate

6

1

Karihtala et al. 2009 [19]

Finland

Ovarian cancer

68

I-IV

41

OS

High

IHC

median

Nuclei

multivariate

6

1

Ma-on et al. 2017 [23]

Thailand

Hepatocellular carcinoma

53

NA

80

OS

High

IHC

IHC score 12

Nuclei

NA

5

2

Xu et al. 2013 [24]

China

Ovarian cancer

72

I-IV

Over 120

OS, PFS

High

ELISA

Fold change

NA

univariate, multivariate

8

1,2

He et al. 2014 [25]

China

Esophageal cancer

144

I-IV

60

OS

High

IHC

percentage of positive tumor cells

Nuclei

multivariate

8

1,2

Shen et al. 2007 [26]

USA

Nonsmall-Cell Lung cancer

99

I-IV

82

OS

High

ELISA

median

NA

multivariate

7

1

Soini et al. 2011 [27]

Finland

Bladder carcinoma

252

I-IV

300

OS

High

IHC

positive > 5%

Nuclei

NA

6

2

Dziaman et al. 2014 [20]

Poland

Colorectal cancer

79

I-IV

100

OS

High

LCEC

median

NA

NA

6

2

Jakovcevic et al. 2015 [21]

Croatia

Breast cancer

145

I-IV

112

OS, DFS

Low

IHC

percentage of positive tumor cells

Nuclei

univariate multivariate

6

1

Pylväs et al. 2011 [29]

Finland

Ovarian cancer

84

I-IV

Over 125

OS

High

IHC, ELISA

percentage of positive tumor cells for IHC. 140 pg/mL for ELISA

NA

univariate multivariate

6

2

Aman et al. 2017 [30]

Japan

Ovarian cancer

95

I-IV

208

OS

High

IHC

percentage of positive tumor cells

Nuclei

univariate

6

1

Matosevic et al. 2015 [31]

Croatia

Colorectal cancer

138

I-IV

169

OS

High

IHC

percentage of positive tumor cells

Cytoplasm

multivariate

7

1

Matsumoto et al. 2003 [32]

Japan

Hepatocellular carcinoma

73

NA

Over 60

CSS, RFS

High

IHC

percentage of positive tumor cells

NA

univariate multivariate

8

1,2

Hintsala et al. 2016 [33]

Finland

Melanoma

121

NA

Over 150

CSS

Low

IHC

NA

Nuclei

multivariate

6

1

Murtas et al. 2010 [34]

Italy

Melanoma

46

I-II

60

OS

High

IHC

percentage of positive tumor cells

Nuclei

multivariate

8

1

Sheridan et al. 2009 [35]

Ireland

Colorectal cancer

113

I-IV

80

OS

High

IHC

NA

Nuclei

multivariate

6

1

Karihtala et al. 2011 [36]

Finland

Breast cancer

79

I-III

60

CSS

Low

IHC

NA

Nuclei

univariate multivariate

6

2

Maki et al. 2007 [37]

USA

Hepatocellular carcinoma

30

I-II

NA

DFS

High

IHC

percentage of positive tumor cells

NA

multivariate

6

1

Pylväs-Eerola et al. 2015 [38]

Finland

Ovarian cancer

105

I-IV

NA

OS, DFS

High

ELISA

median

NA

multivariate

6

1,2

Miyake et al.2004 [39]

Japan

Renal cell carcinoma

72

I-IV

NA

CSS

High

ELISA

mean plus one standard deviation

NA

multivariate

6

1

Sova et al. 2010 [40]

Finland

Breast cancer

150

I-IV

NA

CSS

Low

IHC

percentage of positive tumor cells

Nuclei

multivariate

6

1

  1. OS overall survival, DFS disease free survival, PFS progression free survival, RFS recurrence free survival, CSS cancer specific survival, NOS Newcastle-Ottawa Scale, IHC Immunohistochemistry, ELISA Enzyme-linked immunosorbent assay, LCEC Liquid chromatography electrochemistry, NA not available
  2. *1 denoted as obtaining HRs directly from publications; 2 denoted as HRs were extracted and calculated from Kaplan-Meier curves